Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 1

Status

Completed 4

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4Other hematologic neoplasm 3

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 33Burkitt Lymphoma 20Neoplasm, Residual 9Leukemia 6Lymphoproliferative Disorders 4Lymphoma, Non-Hodgkin 4Lymphatic Diseases 4Leukemia, Biphenotypic, Acute 4Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 3Leukemia, Lymphoid 3Recurrence 2Myelodysplastic Syndromes 2Lymphoma 2Leukemia, Myelomonocytic, Juvenile 2Leukemia, Myeloid, Acute 2Leukemia, Myeloid, Accelerated Phase 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Immunoproliferative Disorders 2Blast Crisis 2Sarcoma, Myeloid 1Philadelphia-Negative ALL 1Philadelphia Chromosome 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Large Granular Lymphocytic 1Hodgkin Disease 1Hematologic Neoplasms 1Down Syndrome 1

Interventions

Cyclophosphamide 5blinatumomab 4Rituximab 3Brentuximab Vedotin 3fludarabine phosphate 2fludarabine 2dacetuzumab 2cobomarsen 2Whole-Body Irradiation 2Vincristine 2Tacrolimus 2Prednisone 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2Mycophenolic Acid 2Mesna 2Melphalan 2Ifosfamide 2Everolimus 2Etoposide 2Doxorubicin 2Carboplatin 2Busulfan 2sepantronium 1pomalidomide 1pembrolizumab 1Vorinostat 1DTRMWXHS-12 1Bone Marrow Transplantation 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Lymphatic Diseases × blinatumomab × Clear all
NCT01207388 2020-02-10

BLAST

Amgen Research (Munich) GmbH

Phase 2 Completed
116 enrolled 23 charts 1 FDA
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Lymphatic Diseases, Lymphoproliferative Disorders, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01466179 2017-08-18

Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)

Amgen Research (Munich) GmbH

Phase 2 Completed
225 enrolled 24 charts
LymphoidOther hematologic neoplasm

Immunoproliferative Disorders, Leukemia, Leukemia, Lymphoid, Lymphatic Diseases, Lymphoproliferative Disorders, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01209286 2017-03-06

Study of the BiTE® Blinatumomab (MT103) in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL)

Amgen Research (Munich) GmbH

Phase 2 Completed
36 enrolled 24 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphatic Diseases, Lymphoproliferative Disorders, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01741792 2017-01-06

Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Amgen Research (Munich) GmbH

Phase 2 Completed
25 enrolled 18 charts
Lymphoid

Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡